Usefulness of presepsin (sCD14-ST) measurements as a marker for the diagnosis and severity of sepsis that satisfied diagnostic criteria of systemic inflammatory response syndrome

Shozushima, Tatsuyori; Takahashi, Goro; Matsumoto, Naoya; Kojika, Masahiro; Okamura, Yoshikazu; Endo, Shunsuke

doi:10.1007/s10156-011-0254-x

Cited by 297 publications

(336 citation statements)

References 5 publications

Supporting

Mentioning

271

Contrasting

Unclassified

Order By: Relevance

“…Acute inflammation may furthermore contribute to CD14 up-regulation by tissues other than monocytes [9]. During recognition of PAMPs by soluble CD14, a 13-kDa fragment is formed, named sCD14 subtype (sCD14-ST) or presepsin [10]. Presepsin is emerging as a novel circulating marker of sepsis [10][11][12][13][14][15].…”

Section: Introductionmentioning

confidence: 99%

“…During recognition of PAMPs by soluble CD14, a 13-kDa fragment is formed, named sCD14 subtype (sCD14-ST) or presepsin [10]. Presepsin is emerging as a novel circulating marker of sepsis [10][11][12][13][14][15]. However, like other candidates in sepsis, this biomarker needs to be validated in large, multicenter studies with representative populations [3].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Circulating presepsin (soluble CD14 subtype) as a marker of host response in patients with severe sepsis or septic shock: data from the multicenter, randomized ALBIOS trial

et al. 2014

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Circulating presepsin (soluble CD14 subtype) as a marker of host response in patients with severe sepsis or septic shock: data from the multicenter, randomized ALBIOS trial

et al. 2014

View full text Add to dashboard Cite

“…During inflammation, the receptor induces cell activation by initiating intracellular signalling cascades [10,55] resulting in rapid gene transcription [56] . RAGE is upregulated in various inflammatory diseases, such as rheumatoid arthritis [57,58] , inflammatory kidney disease [59,60] , arteriosclerosis [61] and inflammatory [71,72] . Presepsin is a promising biomarker for diagnosing sepsis, severe sepsis and septic shock compared to other biomarkers such as PCT [73][74][75][76] and seems specific for infectious diseases [71] .…”

Section: Soluble Receptor For Advanced Glycation End Productsmentioning

confidence: 99%

“…RAGE is upregulated in various inflammatory diseases, such as rheumatoid arthritis [57,58] , inflammatory kidney disease [59,60] , arteriosclerosis [61] and inflammatory [71,72] . Presepsin is a promising biomarker for diagnosing sepsis, severe sepsis and septic shock compared to other biomarkers such as PCT [73][74][75][76] and seems specific for infectious diseases [71] . High plasma levels in septic patients can be detected 6 h after early onset [72] .…”

Section: Soluble Receptor For Advanced Glycation End Productsmentioning

confidence: 99%

Are there new approaches for diagnosis, therapy guidance and outcome prediction of sepsis?

Kojic

Siegler

Uhle

et al. 2015

WJEM

View full text Add to dashboard Cite

Beside many efforts to improve outcome, sepsis is still one of the most frequent causes of death in critically ill patients. It is the most common condition with high mortality in intensive care units. The complexity of the septic syndrome comprises immunological aspects -i.e. , sepsis induced immunosuppression -but is not restricted to this fact in modern concepts. So far, exact mechanisms and variables determining outcome and mortality stay unclear. Since there is no typical risk profile, early diagnosis and risk stratification remain difficult, which hinders rapid and effective treatment initiation. Due to the heterogeneous nature of sepsis, potential therapy options should be adapted to the individual. Biomarkers like C-reactive protein and procalcitonin are routinely used as complementary tools in clinical decision-making. Beyond the acute phase proteins, a wide bunch of promising substances and non-laboratory tools with potential diagnostic and prognostic value is under intensive investigation. So far, clinical decision just based on biomarker assessment is not yet feasible. However, biomarkers should be considered as a complementary approach. Core tip: Sepsis is a complex continuum of disturbed systems. Despite the presence of clinical consensus criteria, the early diagnosis especially in the perioperative setting is challenging. A magnitude of potential new biomarkers is tested for this purpose, but evidence is mounting that due to the complex nature of the syndrome, biomarkers are rather complementary tools for clinical decision making than "magic bullets". Moreover, biomarkers are also evaluated for therapy guidance, linking diagnostic results to an individual therapeutic regime. This review summarizes the developments in the biomarker field, aiming to provide an overview about current targets and their limitations.

show abstract

“…Due to the relatively strong correlation with bacterial infection [73], presepsin may become a specific marker for detection of sepsis and its discrimination from noninfectious SIRS in the future [74,75]. Since the height of the measured plasma levels correlates poorly with the grade of sepsis severity, presepsin appears to be unsuitable as prognostic marker [75].…”

Section: Proadrenomedullin and Soluble Subtype Of The Cd14 Cell Surfamentioning

confidence: 99%

Bacterial sepsis

et al. 2018

View full text Add to dashboard Cite

Usefulness of presepsin (sCD14-ST) measurements as a marker for the diagnosis and severity of sepsis that satisfied diagnostic criteria of systemic inflammatory response syndrome

Cited by 297 publications

References 5 publications

Circulating presepsin (soluble CD14 subtype) as a marker of host response in patients with severe sepsis or septic shock: data from the multicenter, randomized ALBIOS trial

Circulating presepsin (soluble CD14 subtype) as a marker of host response in patients with severe sepsis or septic shock: data from the multicenter, randomized ALBIOS trial

Are there new approaches for diagnosis, therapy guidance and outcome prediction of sepsis?

Bacterial sepsis

Contact Info

Product

Resources

About